Abstract PD1-01: Open-label, randomized, phase 2 study of sapanisertib (TAK-228/MLN0128) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor-2-negative (HER2-) advanced or metastatic breast cancer (MBC) that previously progressed during or after aromatase inhibitor therapy (NCT02756364)
Year: 2021
Type: conference-abstract
Source: Cancer Research
Institutions: Hospital Clínico San Carlos, Hospital Universitario Ramón y Cajal, Hospital General Universitario Gregorio Marañón, Onkologikoa, Hospital San Pedro de Alcántara, Hospital Universitario Son Espases, Centro Oncológico de Galicia, Instituto Murciano de Investigación Biosanitaria, Hospital Universitario Virgen de la Arrixaca, Hospital Universitario Miguel Servet, GEICAM – Spanish Breast Cancer Group, University of California, Los Angeles
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3132298979